Association between Parkinson’s Disease and Helicobacter Pylori

키워드

참고문헌 (35)

1. Memiş S, "Kronik Hastalıklar ve Bakım", pp.277~ (2011), Nobel Tıp Kitabevi
2. Barnum CJ, "Neuroinflammation and non-motor symptoms:the dark passenger of Parkinson’s disease?", Curr Neurol Neurosci Rep, 12, pp.350~358 (2012)
3. Bu XL, "The association between infectious burden and Parkinson’s disease: a casecontrol study", Parkinsonism Relat Disord, 21, pp.877~881 (2015)
4. Tan AH, "Small intestinal bacterial overgrowth in Parkinson’s disease", Parkinsonism Relat Disord, 20, pp.535~540 (2014)
5. Chaudhuri KR, "Non-motor symptoms of Parkinson’s disease: diagnosis and management", Lancet Neurol, 5, pp.235~245 (2006)
6. Simuni T, "Nonmotor manifestations of Parkinson’s disease", Ann Neurol, 64(Suppl 2), pp.S65~S80 (2008)
7. Lim SY, "The nonmotor symptoms of Parkinson’s disease--an overview", Mov Disord, 25(Suppl 1), pp.S123~S130 (2010)
8. McColl KE, "Clinical practice. Helicobacter pylori infection", N Engl J Med, 362, pp.1597~1604 (2010)
9. Franceschi F, "Helicobacter pylori and extragastric diseases", Best Pract Res Clin Gastroenterol, 21, pp.325~334 (2007)
10. Tan HJ, "Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review", J Dig Dis, 13, pp.342~349 (2012)
11. Dobbs RJ, "Parkinsonism:differential age-trend in Helicobacter pylori antibody", Aliment Pharmacol Ther, 14, pp.1199~1205 (2000)
12. Pierantozzi M, "Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations", Neurology, 66, pp.1824~1829 (2006)
13. Lee WY, "Helicobacter pylori infection and motor fluctuations in patients with Parkinson’s disease", Mov Disord, 23, pp.1696~1700 (2008)
14. Dobbs RJ, "Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study", Gut Pathog, 4, pp.12~ (2012)
15. Tan AH, "Helicobacter pylori infection is associated with worse severity of Parkinson’s disease", Parkinsonism Relat Disord, 21, pp.221~225 (2015)
16. Weller C, "Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile", Helicobacter, 10, pp.288~297 (2005)
17. Charlett A, "Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome", Acta Neurol Scand, 99, pp.26~35 (1999)
18. Blaecher C, "Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients", Aliment Pharmacol Ther, 38, pp.1347~1353 (2013)
19. Dobbs SM, "Link between Helicobacter pylori infection and idiopathic parkinsonism", Med Hypotheses, 55, pp.93~98 (2000)
20. Schulz JD, "Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denomenator", Med Hypotheses, 66, pp.1222~1226 (2006)
21. Dobbs RJ, "Helicobacter hypothesis for idiopathic parkinsonism: before and beyond", Helicobacter, 13, pp.309~322 (2008)
22. Kountouras J, "Helicobacter pylori infection and Parkinson’s disease:apoptosis as an underlying common contributor", Eur J Neurol, 19, pp.e56~ (2012)
23. Fasano A, "Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth", Clin Neuropharmacol, 37, pp.91~95 (2014)
24. Pfeiffer R, "Beyond here be dragons: SIBO in Parkinson’s disease", Mov Disord, 28, pp.1764~1765 (2013)
25. Lahner E, "Systematic review: Helicobacter pylori infection and impaired drug absorption", Aliment Pharmacol Ther, 29, pp.379~386 (2009)
26. Niehues M, "In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability?", J Pharm Pharmacol, 61, pp.1303~1307 (2009)
27. Lyte M, "Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori", Med Hypotheses, 74, pp.895~897 (2010)
28. Pierantozzi M, "Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson’s disease patients", Neurol Sci, 22, pp.89~91 (2001)
29. Rahne KE, "Motor fluctuations and Helicobacter pylori in Parkinson’s disease", J Neurol, 260, pp.2974~2980 (2013)
30. Dobbs SM, "Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity", Helicobacter, 18, pp.187~196 (2013)
31. Bjarnason IT, "Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study", Helicobacter, 10, pp.276~287 (2005)
32. Dobbs SM, "Differential effect of Helicobacter pylori eradication on time-trends in brady", hypokinesia and rigidity in idiopathic parkinsonism, 2010, pp.15, 279~294
33. Hashim H, "Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease", PLoS One, 9, pp.e112330~ (2014)
34. Narożańska E, "Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection", Clin Neuropharmacol, 37, pp.96~99 (2014)
35. "Helicobacter pylori eradication in Parkinson’s disease: a double-blind randomised placebo controlled trial" (2014)[URL]

관련 논문AI추천